Fighting infections due to multidrug-resistant Gram-positive pathogens

Clinical Microbiology and Infection

Volumn 15, Issue 3, 2009, Pages 209-211

  Cornaglia, Giuseppe ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; MACROLIDE; OXACILLIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENETICS; BACTERIAL TRANSMISSION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG TREATMENT FAILURE; DRUG USE; EDITORIAL; ENTEROCOCCUS FAECIUM; EPIDEMIC; EUROPE; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEALTH CARE NEED; HEALTH EDUCATION; HOSPITAL POLICY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTERVENTION STUDY; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANCE; OUTCOMES RESEARCH; PATIENT CARE; PENICILLIN RESISTANCE; PHYSICIAN ATTITUDE; PNEUMOCOCCAL INFECTION; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA;

EID: 63249103889     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02737.x     Document Type: Editorial

References (24)

1. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 2008; 14 (suppl 6): 2-8.
2. European Antimicrobial Resistance Surveillance System (EARSS). Annual report 2007. BilthoveH: EARSS, 2008. Available at: http://www.earss.rivm.nl/.
3. Cornaglia G, Hryniewicz W, Jarlier V et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349-383.
4. Prins JM, Degener JE, de Neeling AJ et al. Experiences with the Dutch Working Party on antibiotic policy (SWAB). Euro Surveill 2008; 13: 13.
5. Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect 2003; 9: 1179-1186.
6. Willems RJ, Top J, van Santen M et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11: 821-828.
7. Bozdogan B, Bogdanovich T, Kosowska K et al. Macrolide resistance in Streptococcus pneumoniae: Clonality and mechanisms of resistance in 24 countries. Curr Drug Targets Infect Disord 2004; 4: 169-176.
8. Leclercq R. Epidemiological and resistance issues in multidrug resistant staphylococci and enterococci. Clin Microbiol Infect 2009 (in this issue).
9. Peacock SJ, de Silva GD, Justice A et al. Comparison of multilocus sequence typing and pulsed-field gel electrophoresis as tools for typing Staphylococcus aureus isolates in a microepidemiological setting. J Clin Microbiol 2002; 40: 3764-3770.
10. Dobson R. Report names hospitals with highest proportions of deaths related to MRSA and C. difficile. BMJ 2008; 336: 1211.
11. Ferry T, Etienne J. Community acquired MRSA in Europe. BMJ 2007; 10: 335.
12. Gonzalez BE, Hulten KG, Lamberth L et al. Streptococcus pneumoniae serogroups. 15 and 33: An increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J 2006; 25: 301-305.
13. Lode H. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin Microbiol Infect 2009 (in this issue).
14. Jacobs MR. In vivo veritas: In vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 2002; 35: 565-569.
15. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-1437.
16. Livermore D. Can better prescribing turn the tide of resistance? Nat Rev Microbiol 2004; 2: 7-12.
17. Ramsay C, Brown E, Hartman G, Davey P. Room for improvement: A systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother 2003; 52: 764-771.
18. Cooper BS, Stone SP, Kibbler CC et al. Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: A review of the literature with epidemiological and economic modelling. Health Technol Assess 2003; 7: 1-194.
19. Projan SJ, Shlaes DM. Antibacterial drug discovery: Is it all downhill from here? Clin Microbiol Infect 2004; 10 (suppl 4): 18-22.
20. Boggs AF, Miller GH. Antibacterial drug discovery: Is small pharma the solution? Clin Microbiol Infect 2004; 10 (suppl 4): 32-36.
21. Cornaglia G, Rossolini GM. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect 2009 (in this issue).
22. Cornaglia G, Lönnroth A, Struelens M. Report from the European Conference on the role of research in combating antibiotic resistance, 2003. Clin Microbiol Infect 2004; 10: 473-497.
23. Cauda R, Garau J. New insights into methicillin-resistant Staphylococcus aureus disease: An ESCMID Consensus Conference. Clin Microbiol Infect 2009 (in this issue).
24. Cornaglia G, Garau J, Livermore DM. Living with ESBLs. Introduction. Clin Microbiol Infect 2008; 14 (suppl 1): 1-2.